PIM1 and acute myeloid leukemia: By attacking multiple kinases, including FLT3, PIM1, AURK, and AKT, whose functions are not fully overlapping but all crucial for FLT3-dependent AML growth and survival, palbociclib may reduce the chances of development of FLT3 resistance mutations and lead to more durable clinical responses.